The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Speaker, Faculty, Planners and Authors Conflict of Interest Disclosure: Speaker(s) have no disclosures to declare.
Planning Committee: • Annette Hood discloses that she is a member of the Amgen speakers’ bureau. • Denise Murcek discloses other financial/material support as an employee of the VA Medical Center. • Elizabeth St. John discloses other financial/material support as an employee of Fresenius Medical Care. • Kyra Trappett discloses other financial/material support as an employee of DaVita.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Objectives: • Review the epidemiologic association of uric acid and progression of CKD and CVD. • Discuss the mechanisms by which uric acid causes vascular damage. • Determine why patients with CKD have elevated uric acid. • Analyze clinic trial data on the efficacy of uric acid lowering therapy to treat or prevent hypertension, CKD, and cardiovascular disease.
